University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
USDA National Wildlife Research Center - Staff
Publications

U.S. Department of Agriculture: Animal and Plant
Health Inspection Service

2018

Chapter 11 An International Perspective on the
Regulation of Rodenticides
John D. Eisemann
USDA/APHIS National Wildlife Research Center, John.D.Eisemann@aphis.usda.gov

Penny M. Fisher
Wildlife Ecology and Management Team

Alan Buckle
University of Reading

Simon Humphrys
University of Canberra, Australia

Follow this and additional works at: https://digitalcommons.unl.edu/icwdm_usdanwrc
Part of the Life Sciences Commons
Eisemann, John D.; Fisher, Penny M.; Buckle, Alan; and Humphrys, Simon, "Chapter 11 An International Perspective on the
Regulation of Rodenticides" (2018). USDA National Wildlife Research Center - Staff Publications. 2072.
https://digitalcommons.unl.edu/icwdm_usdanwrc/2072

This Article is brought to you for free and open access by the U.S. Department of Agriculture: Animal and Plant Health Inspection Service at
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in USDA National Wildlife Research Center - Staff Publications
by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

This document is a U.S. government work and
is not subject to copyright in the United States.

Chapter 11

An International Perspective
on the Regulation of Rodenticides
John D. Eisemann, Penny M. Fisher, Alan Buckle, and Simon Humphrys

1

Introduction

In the late 1940s, anticoagulant active ingredients were introduced into the global
rodenticide market. They were rapidly favored over existing rodenticides, such as
red squill, zinc phosphide, strychnine and inorganic compounds, because they were
comparatively inexpensive and did not appear to have any unpalatable taste, odor or
cause any immediate post-ingestive reaction that could lead to bait shyness in rodents
(Wardrop and Keeling 2008). The number of products registered in the United States
(US) under Section 3 of the Federal Fungicide, Insecticide and Rodenticide Act
(FIFRA), which was passed in 1947 and was the first US law to require product
registration, illustrates the rapid dominance of anticoagulants in the US rodenticide
market (Fig. 11.1). It is striking that the number of anticoagulant-based rodenticide
products (ARs) registered under FIFRA was more than two times greater than the
other categories of rodenticide active ingredients 40 years after the enactment of
FIFRA. The greatest number of rodenticide products registered in a single year
under Section 3 of FIFRA (750) was in 1985, and ARs accounted for 547 (73%) of
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Fig. 11.1 Number of rodenticide products registered in the US since passage of the Federal
Insecticide, Fungicide and Rodenticide Act (FIFRA) in 1947. Data presented is only for rodenticide products registered under FIFRA Section 3 and does not include aluminum or magnesium
phosphide, gas cartridges thallium sulfate, or white phosphorous (NPIRS 2014)

those products. Similar data for international markets is difficult to collate, but it is
expected that this rapid rise in popularity was paralleled around the world.
The evolution of pesticide regulations throughout the world followed many different paths. In some countries, including the US and Australia (AUS), the path to
current regulatory paradigms appears to have been built on expanding the scope of
legislation originally enacted to protect consumers from fraudulent products, but
has since evolved to include multiple layers of human health and environmental
protections demanded by an increasingly vocal public. US pesticide regulations are
based on two principal acts, however, multiple human health and safety, and environmental laws also influence the conditions under which a product will be approved
and ultimately used. Like in the US and AUS, New Zealand’s (NZ) road to regulation appears to have been based on a single pesticide law. However, they appear to
have attempted to combine multiple and sometimes conflicting regulations aimed at
human and environmental protection into one umbrella act, which now governs the
use of all hazardous substances, including rodenticides. The most dramatic change
in international pesticide regulation is currently being undertaken in the European
Union (EU), where a massive attempt is being made to consolidate pesticide regulation across individual European Member States into one harmonized set of regulations, agreed upon by all members. This consolidation approach to pesticide regulation
may someday be undertaken on a global scale. However, the difficulties currently
being encountered within the EU from this harmonization effort do not bode well for
future larger scale adoption on any foreseeable time scale. One c ommon thread
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throughout the international pesticide regulatory environments is that pesticide
laws appear to be based on a risk-benefit paradigm, and if products have significant
economic (not necessarily just for manufacturers) and social benefit, products can
be approved for use despite other potential or known risks. To achieve this result,
regulators may impose restrictions on use, typically identified on the product label,
that mitigate the potential hazards a product presents.
The development of pesticide regulation can have a dramatic impact on the availability and use of products. Legislation on a national scale sets the standards for all
subsequent regulatory activities, and these broad laws can have a major impact on
product availability. Another influence, perhaps equally impactful, can be the interpretation of the intent of legislation by regulators charged with enforcing federal
and sometimes state regulations. The rules, guidelines and processes enacted by the
regulatory authorities significantly influence the types of products allowed on the
market, the speed and cost of registering products, and the motivation of private
industry to seek safer uses of ARs or new rodenticide formulations.
Inferences can be drawn as to the impact of regulations by examining the number
of products being brought into or removed from the market. Trends in product registrations in the US illustrate major shifts in product availability (NPIRS 2014).
Some of these shifts appear to be directly the result of significant regulatory change.
For example, the rodenticide product availability in the US grew rapidly between
1950 and 1990 (Fig. 11.1). However, beginning in 1989, the number of rodenticide
products in the US market began plummeting from the high of 750, to the roughly
300 products on the market today. What happened in the US in the late 1980s that
caused this dramatic decrease in product availability?
This chapter examines the historical influences that shaped the current regulatory
environment around rodenticides in US, NZ, EU, and AUS. It compares and contrasts how products are registered, what forces shaped regulatory decisions, and
speculates on the future trends in product availability for rodent control over the
next 25 years. As you will see throughout this chapter, product availability throughout the world has been influenced greatly by increased scientific understanding of
rodenticides’ impact on humans and the environment, and the associated increased
societal demands for safer products and more stringent regulation.

2
2.1

Anticoagulant Rodenticde Regulation in the United States
Legislative Actions

The earliest pesticide legislation in the US was the Insecticide Act of 1910 (P.L.
61–152, 36 Stat. 331), which was enacted primarily to protect consumers from
fraudulent products. Today, there are numerous US federal laws that regulate the use
of pesticides, however, two Acts form the primary framework for pesticide regulation, the Federal Food, Drug and Cosmetic Act (FFDCA), originally enacted in
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1938 [P.L. 75–717, 52 Stat 1040], and the Federal Insecticide, Fungicide and
Rodenticide Act (FIFRA) of 1947 [P.L. 80–104, 61 Stat. 163]. FIFRA ushered in
landmark changes to pesticide regulation, two of the most significant being a
requirement for standardized label language and that all products be registered with
the US Department of Agriculture (USDA) prior to interstate or international shipment. These two actions established the foundation of today’s regulatory environment by centralizing regulatory review under one agency and providing consumers
a means to identify the manufacturer and purity of the product they were purchasing. Since that time, these laws have been amended numerous times and new laws
have been enacted to keep pace with cultural changes and increased scientific
understanding of pesticide chemistry. They now include regulatory considerations
for protecting human health and providing safety from direct and indirect exposure,
special protections for children, limits on the amount of residues allowed in food,
and a wide variety of environmental protections.
Prior to the 1970s, pesticides were regulated by the USDA, and the general tenor
of the regulations favored agribusiness (Carson 1962). However, an increasing segment of US society considered pesticides to be under-regulated. There was growing
fear that FIFRA and the FFDCA failed to provide adequate guidance on the proper
use of pesticide products, and that insufficient data were required of manufacturers
to support product registrations (Carson 1962). Consequently, many felt it was
impossible for regulators to assess the potential human and environmental risks
associated with pesticide use. Arguably the foremost publication that galvanized
public sentiment against what was perceived to be an over-promoted and under-
regulated pesticide industry was Rachael Carson’s ‘Silent Spring’ (Carson 1962).
Silent Spring served as a rallying call for splintered concern over unknown pesticide
impacts and spurred private citizens and public interest groups to mount political
pressure for pesticide reform (Bosso 1988). The first Earth Day in the US occurred
in 1969. In 1970, President Richard Nixon established the US Environmental
Protection Agency (US EPA, 35FR 15623, 84 Stat. 2086) and at the same time,
transferred regulatory oversight of pesticides from the USDA to the US EPA.
Two major legislative actions occurred in 1972, the Congress amended the predecessor to the Endangered Species Act (P.L. 93–205, December 28, 1987, 87 Stat.
903) to define imminent hazard to include situations involving unreasonable hazard
due to the survival of a threatened or endangered species, including pesticides and
Congress amended FIFRA with the passage of the Federal Environmental Pesticide
Control Act (FEPCA, P.L. 92–516, October 21, 1972, 86 Stat. 973). The FEPCA
included four actions that significantly impacted the use of pesticides. First, it
required a systematic review of pesticide labels and supporting data for all products
registered with the US EPA. Second, it established the risk standard of ‘unreasonable adverse effects’ defined it as ‘any unreasonable risk to man or the environment,
taking into account the economic, social, and environmental costs and benefits of
the use of a pesticide.’ Third, the Act mandated that, in addition to US EPA evaluating the risk to human health and the environment posed by pesticide product, US
EPA must also consider the benefits of continued use, primarily economic benefits.
Finally, the Act also established a dual classification system for pesticide products,
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General Use and Restricted Use. General Use products were those found to be safe
when used according to label directions and could be sold to general consumers.
Restricted Use products are those found to have a higher potential for risk when
used according to label directions, and would only be available to trained certified
applicators.
US EPA faced a daunting task under the FEPCA. At the time the law was passed,
US EPA oversaw product registrations that included hundreds of active ingredients
and thousands of end-use-products and associated degradates. The US EPA was
required to implement all aspects of the FEPCA for all existing and new products
within 4 years of passage. By the mid-1970s, EPA began releasing ‘Registration
Standards’ which summarized the available data supporting a product registration
and, if necessary, required additional data be submitted. These data were used to
conduct human health and environmental assessments to assess the potential risk
when pesticide products were used in accordance with label directions. When label
directions were assumed to lead to unreasonable adverse effect(s), product use was
restricted by modifying label language and/or additional data was required to further understand the potential risk. Registration Standards for rodenticide products
began to be issued in 1981 for the first active ingredient, warfarin.
The next major revision to US pesticide laws came in the form of amendments to
FIFRA in 1988 (P.L. 100–532, October 25, 1988, 102 Stat. 2655). These changes
were prompted in part because of the slow progress US EPA was making in product
reviews under the FEPCA. The principal changes to FIFRA were the standardization of chemical review methods and concurrent implementing process in which
registrants were required to identify and commit to submitting missing or additional
data required by EPA. This process culminated in US EPA’s comprehensive examination of product label language and data submitted in support of continued product
registration or ‘re-registration,’ and issuance of Registration Eligibility Decisions
(REDs). With renewed emphasis on the speed and comprehensiveness of regulatory
review, the US EPA required registrants to submit thousands of missing or invalid
studies on pesticide active ingredients, degradates, and end-use products. Because
of the significant financial investment required to keep products on the market and
pressure on US EPA to restrict or eliminate the use of the most hazardous products,
the number of pesticide registrations began to decline. As observed by the product
registration trend lines in Fig. 11.1, the 1988 amendments to FIFRA had significant
impacts on the availability of all rodenticide products. At the peak of the US rodenticide market in 1985, 750 rodenticide products were registered with the US EPA.
By 1994, the number of rodenticide products had plummeted to about one-half of
that number.
The dramatic decline in product registrations was not primarily due to US EPA’s
determination that the products were too hazardous to be registered. Rather, most
products were voluntarily or passively cancelled because registrants declined to pay
the registration fees or cost necessary to maintain the registration (Jacobs 1992).
According to Jacobs (1992), between 1989 and 1991, 52% of all pesticide products
(not limited to rodenticides) registered under FIFRA Section 3 were cancelled due to
registrant’s failure to pay the increased annual registration maintenance fees imple-

292

J.D. Eisemann et al.

mented by the 1988 amendments to FIFRA. While Jacobs (1992) does assign a dollar value to the cost associated with the 1986 US EPA Data Call-In and 1988
amendments to FIFRA, it is speculated that this increased cost to keep low value
pesticides on the market contributed to a dramatic increase in product cancellations.
While there have been other amendments to FIFRA and the FFDCA since 1988,
the legislation that most significantly impacted human health and safety issues
related to pesticide use was the Food Quality Protection Act (FQPA) of 1996 (P.L.
104–170, August 3, 1996), which amended the FFDCA and FIFRA. FQPA regulations covered all pesticides, including rodenticides, but because there are few rodenticide food or feed uses, the impact was not as large as on conventional agricultural
pesticides.

2.2

Legislation Implementation Actions

Laws passed by the US Congress form the regulatory framework for pesticide markets and those laws can have wide ranging impacts. However, in many instances, the
implementation processes established by regulatory authorities, or judicial interpretation of the laws or implementation processes, can have an even more dramatic
impact of the availability and use of pesticide products. A perfect example of this
can be observed by examining the regulatory history of strychnine-based products.
Insights into the future of ARs can be drawn from this case study.
Strychnine: A case study in the non-legislative impacts on product availability in
the US
In 1947, the year FIFRA was enacted and product registrations were required,
strychnine-based products accounted for 85% of all rodenticide products registered
with the USDA. Today they account for less than 10% of the US rodenticide market
(Fig. 11.2). The demise of strychnine can be attributed to increased competition
from other rodenticide active ingredients, including the introduction of ARs, but
also to mounting evidence of significant negative impacts on non-target species,
sustained vocal public opposition to continued use, and the response of regulatory
and non-regulatory bodies.
A growing concern for non-target hazards posed by above-ground uses prompted
President Richard M. Nixon to issue an Executive Order (Executive Order 11643)
prohibiting the use of all toxicants, including strychnine, for controlling predatory
mammals and birds on federal lands or in federal programs. By 1976, US EPA’s
technical review of the supporting data and consideration of input of concerned parties resulted in a determination that strychnine presented unacceptable risk to applicators and non-target species, and they issued a notice on the Rebuttable Presumption
Against Registration (RPAR) against all outdoor, above-ground uses of strychnine
products (41 FR 52810, December 1, 1976). By 1983, US EPA published a notice
of its intent to restrict all strychnine products to a maximum concentration of 0.5%,
and to cancel registration of strychnine for above-ground use against most target
species, including prairie dogs and meadow mice (48 FR 48523, October 19, 1983).
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Fig. 11.2 Percent of rodenticide products registered under FIFRA that contain strychnine, other
acute toxicants, and anticoagulant active ingredients since 1947 (NPIRS 2014)

Following EPA’s 1983 announcement, a series of judicial challenges were filed
on behalf of agricultural and environmental interests, including among others the
Wyoming Department of Agriculture, Defenders of Wildlife, and Sierra Club (Wade
1985; Defenders of Wildlife 1988). In 1988, the US Circuit Court in Minnesota
issued an injunction against all above-ground uses of strychnine to protect non-
target species (Defenders of Wildlife 1988). To this date, US EPA has not approached
the US Circuit Court with proposals to modify the injunction against above-ground
uses of strychnine, and all current uses of strychnine products are limited to below-
ground applications to manage pocket gophers.
Most recently, in December 2009, the State FIFRA Research and Evaluation
Group (SFIREG), a group composed of representatives from State pesticide regulatory authorities, petitioned US EPA to reclassify all strychnine products as Restricted
Use products (US EPA 2009). At the time of writing this chapter, all of the responses
to US EPA’s request for comments supported the petitioner’s request, but the US
EPA has not publically acted on this petition. However, US EPA has recently begun
another review, ‘Registration Review,’ and published a final work plan in June 2016
(US EPA, 2016b). It is possible US EPA is withholding any action on this petition
until they complete their re-evaluation in 2021.
The legislative regulatory path of strychnine was not unlike all other pesticides
regulated by the US EPA under FIFRA and the FFDCA. The decrease in the market
share of strychnine products from 1988 to 1996 (Fig. 11.2) can be linked to the 1988
injunction levied by the US District Court in Minnesota against above-ground uses
to control rodents, but also to the impact of the legislatively-required periodic
review of pesticide products and associated data requirements. The regulatory history of strychnine may serve as a harbinger of the future of ARs. Second generation
anticoagulant rodenticides (SGARs) have not been proposed for cancellation by the
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US EPA. However, mounting evidence of non-target impacts and the constant
public pressure against their continued use may ultimately lead to a shrinking role
for them in the future rodenticide market.

2.3

 egulatory Implementation Actions on Anticoagulant
R
Rodenticides

In 1947, US EPA began an aggregate risk and benefit analysis of common AR products in the 1990s. They published their analysis in the Registration Eligibility
Decision (RED), Rodenticide Cluster (US EPA 1998). US EPA concluded that all
uses of brodifacoum, bromethalin (not an AR), and bromadiolone were eligible for
registration. Chlorophacinone and diphacinone and its sodium salt, were also suitable for registration, with the exception of some field uses. Pival was ineligible for
re-registration because the registrant failed to respond to the Agency’s Data Call-in
Notice.
For products remaining on the market, US EPA began a two-phase approach to
mitigating environmental and human health impacts. Phase One included short-
term mitigation measures such as classification of all tracking powders and field use
products as Restricted Use Pesticides, the addition of an indicator dye (later abandoned), new labeling requirements designed to clarify proper placement in and
around buildings, and registrants were required to submit annual summaries of accidental poisonings compiled by the American Association of Poison Control Centers.
Phase Two was aimed at longer-term risk mitigation measures primarily focused on
prompting the rodenticide industry to develop safer application technologies.
While these proposed mitigation measures were playing out between US EPA
and industry, US EPA began an in-depth environmental risk assessment of nine
active ingredients used in rodenticide products and published their findings in 2004
(Erickson and Urban 2004). This risk assessment advanced US EPA’s standard stochastic risk assessment methods to include probabilistic risk assessment techniques.
They identified that products containing brodifacoum, difethialone, and zinc phosphide presented the greatest overall hazard to birds and non-target wildlife. In addition, baits formulated with loose grains presented the highest ecological hazard.
In 2008, EPA published a final decision on risk mitigation measures for rodenticide products intended to reduce the potential of accidental exposure in children,
companion animals, and environmental risk (Table 11.1, US EPA 2008). The rodenticide industry was given 3 years to comply. Most product manufacturers responded
by voluntarily cancelling less profitable products and changing other product formulations and use patterns to comply with the new guidelines. The few registrants
who initially challenged US EPA’s authority to implement these measures finally
complied in 2014 (US EPA 2014). The impact of these mitigation measures can be
observed in the slight drop in the number of products containing SGARs beginning
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Table 11.1 Rodenticide risk mitigation measures enacted by US EPA (US EPA 2008)
To reduce risk to children
All “consumer size” rodenticide bait
products must be sold packaged together
with a ready-to-use (prebaited) bait station.
Only the active ingredients
chlorophacinone, diphacinone, warfarin,
bromethalin, cholecalciferol, and zinc
phosphide were allowed in consumer sized
baits. New bait station design and testing
standards were developed and a 4 tier suite
of bait stations were identified.
Bait stations may be (1) non-refillable
(disposable, one-time use stations), or (2)
refillable (sold with bait refills). Consumer
size bait stations was limited to a total of 1
pound of bait (initial load and refill
combined). Bait refills must be sold with a
bait station.
Meal, treated whole-grain, pelleted, and
liquid forms of bait were prohibited except
in agricultural sites. Bait blocks were the
only form of bait approved for consumer
size products.
Below ground uses were excluded from bait
station and bait block requirements.

To reduce risk to non-target birds and Mammals
Minimum package size requirements in order to
minimize the availability of second-generation
anticoagulant products on the general consumer
market. Second-generation bait products must be
sold in packages that contain >8 pounds of bait
for products that are labeled for use only inside
of and within 50 ft of agricultural buildings and
not for use in and around the home. For products
intended for use by professional applicators, the
minimum permissible amount of bait per
package is 16 pounds.
Use site restrictions on products containing
brodifacoum, difethialone, difenacoum, or
bromadialone. Products containing at least 8 but
not more than 16 pounds of bait may only be
used in and around (within 50 ft) of agricultural
buildings (e.g., barns, hen houses), and bear the
statement “Do not use this product in homes or
other human residences.’
Sale and distribution restrictions on products
containing brodifacoum, difethialone,
difenacoum, or bromadialone such that they can
only be sold or distributed in agricultural stores
or to Pest Control Operators.
Bait station required for outdoor above-ground
placements of second generation anticoagulants.
Tamper resistant bait stations are required if the
placement is within reach of pets, domestic
animals, non-target wildlife, or children under
6 years of age.

in 2008, and a slight increase in the number of registrations of products containing
acute toxicants (Fig. 11.3).
In the US, State governments have the right under FIFRA to enact rules and regulations that further restrict the use of pesticide products within their State. California
exercised that right in 2014 in an effort to address a state-wide problem of wildlife
exposure and poisoning from products containing SGARs. Assembly Bill No. 2657
prohibits the use of brodifacoum, bromadiolone, difenacoum, and difethialone in
‘wildlife habitat areas’, including state parks, state wildlife management areas, or
state conservancy areas. In 2016, Assembly Bill 2596, a far more sweeping prohibition on the use of rodenticides, was introduced into the California Legislature. If
passed as proposed, the California Natural Predator Protection Act of 2016 (proposed name) would read as follows ‘…the use of any pesticide that contains one or
more of the following anticoagulants is prohibited in this state: brodifacoum, bromadiolone, chlorophacinone, cholecalciferol (not an AR), difenacoum, difethialone,

296

J.D. Eisemann et al.

100
90

Percent of Registered Products

80
70
60
50
40
30
20

0

1947
1949
1951
1953
1955
1957
1959
1961
1963
1965
1967
1969
1971
1973
1975
1977
1979
1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013

10

Acute Toxin Products

1st Gen Anticoagulants

2nd Gen Anticoagulants

Fig. 11.3 Percent of rodenticide products registered under FIFRA that contain acute active ingredients and 1st and 2nd generation anticoagulant active ingredients since 1947 (NPIRS 2014)

diphacinone, warfarin.’ Both California bills exempt agricultural uses of ARs from
the prohibitions.
In 2016, US EPA announced their efforts to develop a new web-based system,
Bulletins Live 2, which will provide pesticide applicators with guidance on whether
the proposed pesticide use is prohibited spatially or temporally because of potential
risk to threatened and endangered species (T&E) (US EPA 2016a). Working in conjunction with the U.S. Fish and Wildlife Service, Endangered Species Office, this
system will have the benefit of providing species range maps at the township level,
perhaps allowing applications in counties where they might have been previously
prohibited because previous maps were based on county-level species occurrence.
This system might also further to restrict pesticide applications because the ability
to respond to changes in known species ranges is much quicker than the old system
requiring T&E species prohibitions listed on individual labels. Despite EPA’s current efforts, the benefits of this system on a wide-scale will not be realized for years
into the future. There are only a limited number of bulletins currently available on
the EPA website 
(https://www.epa.gov/endangered-species/endangered-speciesprotection-bulletins).
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Anticoagulant Rodenticide Regulation in New Zealand
 he Agricultural Compounds and Veterinary Medicine
T
Act 1997

Currently, seven AR compounds are registered in NZ as the active ingredient in
formulations classed as ‘vertebrate toxic agents’ (VTAs). A VTA is a subset of
‘agricultural compounds’ as defined under the Agricultural Compounds and
Veterinary Medicines (ACVM) Act 1997 (Public Act 1997 No. 87). The Approvals
and ACVM Group sits within the Ministry for Primary Industries and is responsible
for developing, implementing and confirming compliance to the NZ approval processes under the ACVM Act, alongside other legislation and amendments. The purpose of the ACVM Act is to prevent or manage risks associated with the use of
VTAs, including risks in trade of agricultural produce, public health, animal welfare
and agricultural security. In addition, the Act is to ensure that there are no breaches
in domestic food residue standards and that there is provision of sufficient consumer
information about the VTA products.
Formulations of VTAs are generally trade name products used to kill, control, or
limit the viability of vertebrate pests. All VTAs imported, manufactured, sold or
used in NZ must be authorized under the ACVM Act and Regulations, under one of
three types of authorization: (i) registration of a specific trade name product under
section 21 of the ACVM Act, which is essentially an approval to promote, advertise,
or sell a VTA, (ii) provisional registration to undertake research to obtain information to determine whether a VTA should be registered, and (iii) approval in special
circumstances to allow conditional VTA use without registration or provisional
registration.
The New Zealand Ministry for Primary Industries (MPI) is responsible for registration of VTAs, which undergo a technical appraisal and risk assessment of their
quality, humaneness (relating to animal welfare) and efficacy. During registration,
MPI determines which of three categories apply to a VTA: (i) unrestricted sale and
unrestricted use, (ii) restricted sale and unrestricted use, or (iii) restricted sale and
restricted use. Unrestricted sale and use VTA products (over-the-counter or OTC)
have no restriction on their sale, no expectation of trace-back through the wholesale
or retail trade, and no notification or signage requirements around their use. They
may be promoted in ways to ensure that potential users are properly informed about
the products and used within the conditions of registration. Generally this category
includes poisons used in small quantities for domestic, non-commercial pest control
and includes a range of first generation AR (FGAR) and SGAR actives. Table 11.2
summarizes the number of products containing ARs as the active agent currently
registered in NZ, which includes both restricted and unrestricted products.
The ‘restricted sale, unrestricted use’ VTA product category requires additional
instruction or advice (over and above the label information) at the point-of-sale to
ensure that they are used appropriately, which may also entail additional recording
of distribution or sales. This group includes some products used for commercial pest
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Table 11.2 Anticoagulant compounds that are active agents in currently-registered vertebrate
toxic agent formulations, available as products in NZ as of 2016 (MPI 2016).
Anticoagulant Active Ingredient
Brodifacoum
SGARa
Bromadiolone
SGAR
Coumatetralyl
SGAR
Difethialone
SGAR
Diphacinone
FGARb
Flocoumafen
SGAR
Pindone
FGAR
TOTAL

Number of
products
20
6
3
3
8
1
4
45

First year a product
was registered
1996
1981
1980
2013
1984
2003
1992

Most recent year a
product was registered
2016
2013
1999
2014
2015
2003
2001

aSecond Generation Anticoagulant
bFirst Generation Anticoagulant

control that can be sold only by persons approved by the ACVM Group. They may
be required to maintain records of sale, particularly if it is considered necessary to
have a trace-back capability. Users purchasing such products do not have to be
approved. ‘Restricted sale and use’ VTA products have conditions on both sellers
and users, whereby both parties need to be approved by the ACVM Group. Restricted
sale and use VTA trade name products must not be promoted or advertised.

3.2

The Hazardous Substances and New Organisms Act 2001

The development of the Hazardous Substances and New Organisms Act 1996 (the
HSNO Act) began in 1988 when the Interagency Co-ordinating Committee on
Pollution and Hazardous Substances recommended that a new legislative framework for controlling hazardous substances be developed. Previously, chemical and
biological products in NZ were regulated under a range of legislation (Thompson
1973). Each piece of legislation was directed towards a particular product type or
aspect of its use, e.g. the Pesticides Act 1979, the Animal Remedies Act 1967, the
Toxic Substances Act 1979, the Explosives Act 1957, the Plants Act 1970, and the
Dangerous Goods Act 1974. One critique was that these statutes were often inconsistent and required implementation by a range of agencies with different regulatory
missions (Allen and Clark 2006). In order to implement a more streamlined, better-
practice approach to managing hazardous substances, a “One Act, One Authority”
model was agreed upon. The HSNO Act consolidated existing legislation, and the
Ministry for the Environment was charged with administering the legislation with
support from the newly formed Environmental Risk Management Authority NZ and
its operational agency (ERMA NZ). This agency was disestablished on June 30,
2011, and its functions were incorporated into the NZ Environmental Protection
Agency (NZ EPA).
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The HSNO Act reformed the way that hazardous substances are dealt with in
NZ. As part of the consolidation process, all existing hazardous substances were
transferred from the multiple-legislation regime. In 1997, the NZ Pesticide Board
was still operational (Eason et al. 1997) and considering criteria for reassessment of
VTAs registered before 1980 (e.g., sodium fluoroacetate, cyanide, phosphorus, pindone). After a series of transitional provisions to allow for the continued manufacture and importation of products that were legally used in NZ before commencement
of new legislation, the HSNO Act came into full effect on July 2, 2001. The HSNO
Act aims to prevent, mitigate or otherwise manage the adverse effects that hazardous substances and new organisms pose to the health and safety of people and environmental health, by managing the substances throughout their life cycle (i.e., in
respect to manufacture, importation, sale, use and disposal in NZ). A product
requires approval under the HSNO Act if it is a substance with one or more hazardous properties that exceeds a prescribed threshold. The definition of substance in
this legislation is broad and covers mixtures of chemical and biological compounds
such as household detergents, industrial reagents, and agricultural compounds –
including ARs and their formulations in bait.
For a substance without a pre-existing approval, the HSNO Act places the onus
on the manufacturer or importer to provide sufficient data describing the hazardous
properties of their product. It is on this information that a determination is based, as
to whether or not a product is hazardous and therefore, requires approval. Once a
product is approved, any manufacturer or importer may rely on that approval; an
exception to this general rule is where the product is also an innovative agricultural
compound or medicine, and this could include some anticoagulant VTAs. Although
applicants may identify information submitted in support of an approval application
as being confidential, situations may arise where this information can be released to
the public.
Section 140 of the HSNO Act provides for regulations to be made to support the
implementation of the Act. The most relevant regulations are general sets of regulations that outline the skills and knowledge required to hold office under the HSNO
Act, and regulations that classify hazardous substances and set out control mechanisms that must be applied when dealing with these. Other sets of regulations relate
to the information requirements that must be used (i.e., labelling, packaging, signage, advertising, documentation and tracking requirements).
Section 78 of the HSNO Act enables the Environmental Protection Agency New
Zealand (EPA NZ, previously ERMA) to issue, amend, approve, or revoke an
approved code of practice (ACOP) regarding the control of a hazardous substance.
This section also gives EPA NZ the ability to approve codes of practice developed
by other people if it considers these to be acceptable.
Section 79 of the Act sets out the consultation and notification process that must
be undertaken as part of the approval process whereby a HSNO ACOP provides a
mechanism to assist people to achieve compliance with the controls set out in the
legislation. In the case of ARs, a code of practice has been developed for the broadcast application of a particular formulation of brodifacoum bait for rodent eradication (Anonymous 2006).

300

3.3

J.D. Eisemann et al.

Anticoagulant Rodenticide Use in New Zealand

As of June 1972, there were 1126 fully registered and 180 provisionally registered
products containing agricultural chemicals, of which 11 were classified as rodenticides (Thompson 1973). Warfarin was historically used in NZ for rodent control,
with at least two commercial bait formulations registered by the Pesticides Board,
but these registrations apparently lapsed in June 2000.
There is no formal reporting information publically available regarding the
annual retail sales and quantities of some ARs used for commensal rodent control.
Therefore, it is difficult to determine the overall and proportional uses for commensal control by (i) the general public who purchase ARs through various retail outlets,
(ii) owners or managers of businesses where there is a formal regulatory mandate
for rodent control, or (iii) professional pest control companies that are contracted by
private individuals or businesses to undertake rodent control in and around
buildings.
All currently-registered ARs in NZ (Table 11.2) target Rattus norvegicus, R. rattus, R. exulans and/or Mus musculus, however, brodifacoum formulations are currently also used for brushtail possum (Trichosurus vulpecula) management, and
pindone formulations for possum and rabbit (Oryctolagus cuniculus) management.
Neither chlorophacinone nor difenacoum appears to have yet been registered in
NZ. In contrast to the USA and EU, there have not been any recent significant
changes to the ways in which ARs are registered or regulated in NZ. However, perhaps in response to increased restriction and decreased markets for SGAR products
in other places, in the last 4–5 years, there has been a marked flurry of new registrations (Fig. 11.4), such that there are now more products containing SGARs than
ever before ‘on the books’ in NZ .
There are two broad use patterns for ARs in NZ: the control of rodents (rats and/
or mice) living commensally with human habitation (“commensal control”) and
field application for management of populations of targeted pests (rodents, possums, rabbits). Commensal control is where bait is applied in and around buildings
or structures that can harbor rodents including residential households, farm buildings, factories, warehouses, commercial food handling premises, and on boats. The
use of over-the-counter ARs, alongside trapping, are probably the most commonly
used method for commensal rodent control in NZ, and a variety of bait formulations
containing SGARs are widely retailed to general public.
The second broad use pattern of ARs is for ‘field control’ of pest animals. ARs
are generally not applied for arable crop protection in NZ, however, a globally distinctive use pattern covers control of pest animals living in situations removed from
human habitation (“field control”), which can include bush/pasture margins, forested areas, dune/coastal areas, conservation estate and offshore islands. Almost
exclusively, these aim to protect biodiversity values from the impacts of rats, and
other introduced mammals, as predators or competitors of native NZ fauna and
flora. They are also to manage possum populations as wildlife vectors of bovine
tuberculosis. Perhaps the most notable NZ field use pattern is aerial broadcast
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Fig. 11.4 Numbers of currently registered vertebrate toxic agents in New Zealand containing
anticoagulants as actives, showing which year these products were first registered. Does not show
discontinued or deregistered vertebrate pesticides (MPI 2016)

a pplication of brodifacoum for control of rodents on non-stocked offshore islands or
mainland areas enclosed by an effective pest-proof fence. This usage is strictly limited to the Department of Conservation and authorised persons, subject to a formal
Code of Practice (Anonymous 2006). While this is not a frequent use, applications
can be on a very large scale to facilitate the eradication of rodents from offshore
islands where reinvasion can be prevented (Fisher et al. 2011).

4

 egulation of Anticoagulant Rodenticides in the European
R
Union

Anticoagulant rodenticides are widely used in the EU for rodent pest management.
The sale and use of ARs in the EU is regulated under two different legal instruments. Those applied to growing crops are known as ‘pesticides’ and are subject to
regulation under the Plant Protection Products Directive (European Council 1991),
and the subsequent implementing Regulation (European Council 2009). Those
applied for all other uses, considered to be biocides, are regulated under different
legislation, the Biocidal Products Directive, and known as the BPD (European
Community 1988). Having two different regulatory procedures for the same
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substances necessitated a clear dividing line between them to prevent duplication of
effort. After considerable consultation and deliberation, the European Commission
(the Commission) made this dividing line the ‘field gate’. In other words, if ARs are
used to protect any crop ‘in field’, whether the crop is actually growing or stored
(e.g., clamps of root vegetables), such uses are considered to be pesticides for crop
protection. Any ARs applied beyond the field, and such uses are extremely varied
but include the storage of processed agricultural produce within farm buildings, are
considered biocides (European Commission 2005, 2015).
Applications of ARs in Europe for plant protection are relatively few. There are
several reasons for this. Firstly, rodent pest pressure in European agricultural is
somewhat limited, although of course, rodent pest damage to a range of agricultural
and forestry crops is well-documented, especially in southern European countries
with warmer climates (Buckle and Pelz 2015). The second and probably more
important reason for the restricted use of ARs in European crop protection is that
mitigation measures are largely unavailable to prevent environmental impacts in
these uses (see Chap. 12). The balance between risk and benefit is therefore tilted
significantly against such applications when product authorisations are considered
by regulators. Hence, by far the greatest quantities of ARs are applied in the EU as
biocides to protect human and animal health. The remainder of this section will deal
mainly with regulation of such uses.

4.1

The Biocidal Products Directive and Regulation

Until the development and implementation of the EU’s BPD (European Community
1998), the regulation of ARs in Europe was conducted through a series of national
statutes and other country-specific legal regulatory instruments. In some countries,
such as the UK where the Control of Pesticides Regulation (1986) (COPR) as
amended (1997) was in force (Health and Safety Executive 2016), anticoagulants
were fully regulated according to strict UK national requirements. In other European
countries, Germany for instance, there was little or no formal regulation of rodenticides. This situation underwent fundamental change with the introduction of the
BPD, and with the subsequent implementing Regulation, the Biocidal Products
Regulation (BPR) (European Union 2012). This regulation encompasses ARs, and
a wide range of other common biocides such as insecticides, disinfectants, wood
preservatives, and anti-fouling agents, as well as less some less widely-used chemicals, such as embalming fluids, metal-working fluid preservatives, piscicides, and
others (Knight and Cook 2002).
One of the principal objectives of the EU is to promote free flow of products and
services between Member States (MSs), without the imposition of unnecessary
regulatory barriers. Clearly, in terms of the movement and use of ARs across Europe,
this requires a common framework of regulation of use practices, product registrations (termed authorisations in the EU) and product labelling. The BPD was developed to provide this framework for chemical biocides. The main, and highly
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laudable, regulatory principle of the BPD was to implement the highest possible
standards of protection of human health and the environment (European Community
1998). This is explicit in the eighth of the ‘whereas’ clauses that conventionally
precede all EU Directives, as follows:
Whereas it is necessary, when biocidal products are being authorised, to make sure that,
when properly used for the purpose intended, they are sufficiently effective and have no
unacceptable effect on the target organisms such as resistance or unacceptable tolerance,
and, in the case of vertebrate animals, unnecessary suffering and pain, and have, in the
light of current scientific and technical knowledge, no unacceptable effect on the environment and, in particular, on human or animal health;

It is apparent from other chapters in this book that all of the issues raised in this
clause, including resistance, humaneness, and non-target impacts, are relevant considerations in the regulation of the ARs in Europe and elsewhere.
The aims of the European regulators who framed this Directive are supported by
everybody, including country authorities, manufacturers, and users, but the vast cost
of delivering them has been almost exclusively borne by the industry that develops
and puts ARs and other biocides onto the European market (Buckle 2002). These
costs (see Adams 2005) have had a stifling effect on research and innovation,
because funds which would have supported new product development have been
diverted for two decades into projects aimed at keeping old ones on the market. A
key benefit of the BPD/BPR presented to industry, and one keenly sought by the
Commission, was reduced regulatory costs resulting from harmonized regulation
across the EU. In other words, similar (or even the same) products having the same
use patterns and risks, being regulated in a similar way among all EU countries.
This benefit has remained almost entirely unrealized because of a failure to agree
common regulatory principles affecting ARs among the Member States of the EU
(see examples below).

4.2

Operation of the Biocidal Products Directive

The Commission, the executive body of the European Parliament and Union, is the
agency which proposed legislation for regulating biocides and is now charged with
implementing decisions of the Parliament in respect of the BPR. However, as with
many other European regulatory schemes, implementation ‘on the ground’ is multi-
layered and another organization, the European Chemicals Agency (ECHA), manages the technical, scientific and administrative aspects of implementation. It does
this by providing guidance to, and in consultation with, MS regulatory authorities,
which are called ‘Competent Authorities’ (CAs). This European system of regulation of biocides was preceded by the implementation of a system with similar aims
for the regulation of crop protection chemicals. Therefore, in many respects, the
operation of the BPD/BPR is similar to the operation of the Plant Protection Products
Directive (PPPD)/Plant Protection Products Regulation (PPPR) which preceded it.
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Regulatory permission to place a biocidal product on the market in the EU is
conducted in two stages. In the first, the properties of active substances and the risks
of their applications are assessed. This is done by the presentation to the Commission,
by a manufacturer of an active substance, of a dossier of studies that addresses a
required list of chemical, toxicological, and environmental ‘end points’, which are
set out at Annex II of the BPR (European Union 2012). The method of dossier submission is via an electronic portal operated through the ECHA website called the
Register for Biocidal Products (R4BP), now in its third version R4BP3.
The initial assessment of the dossier is conducted by the CA of a Member State
nominated by ECHA – the evaluating Member State (eMS or eCA). The eMS completes a draft Assessment Report and publishes its conclusions within a year, which,
after a permitted 30-day period for comment by the applicant, is submitted to the
ECHA Biocidal Products Committee (BPC) for peer review. This review provides a
270-day period for comment and amendment of the eMS’s draft Assessment Report
and its conclusions by the CAs of all other EU Member States. The final Assessment
Report is completed by the Biocidal Products committee (BPC) of ECHA and an
opinion submitted to the Commission for a decision on the approval of the active
substance. The cost of these procedures, borne by the applicant, vary depending on
the nature and scope of the dossier and the cost to the manufacturer of the services
provided by the eMS, but are in the range €100 k to €500 k (~US $113,000 to
$565,4000) to per active substance, with additional fees payable to ECHA (European
Union 2013). This process results in the addition of the active substance to the
Commission’s list of approved active substances.
Article 5 of the BPR makes provision for active substances to be refused approval
if they possess one or more of the properties listed in it as ‘exclusion criteria’. This
is the case for the ARs, because they are considered to be both toxic to reproduction
and are named potential PBTs (persistent, bio-accumulative, and toxic). However,
provisions exists for the derogation of exclusion if “the active substance is essential
to prevent or control a serious danger to human health, animal health or the environment” or “not approving the active substance would have a disproportionate
negative impact on society when compared with the risk to human health, animal
health or the environment arising from the use of the substance.” One or both of
these derogations are considered to apply to ARs, and they have been approved for
use throughout the EU. Nevertheless, when such derogations are invoked, active
substances to which they are applied are named ‘candidates for substitution’. These
are then approved only for 5 years (instead of the usual ten) and are subject to a
review process every 5 years, which involves a public consultation. The public consultation on ARs conducted by ECHA at the first renewal of these active substances
(i.e., 5 years after first approval) has just closed at time of writing. The consultation
is carried out to determine whether equally effective and safer alternatives to the
candidates for substitution have become available. As there are none, ECHA has
come to the conclusion that all AR active substance approvals will be renewed for a
further 5 years.
A second and different regulatory procedure is applied to the assessment of products containing approved active substances – with further substantial fees in the
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region of €100 k (~US $113,000) per biocidal product payable to MS bodies that
conduct assessments. If an applicant wishes to sell a product in only one MS, an
application for authorization of the product is made to the MS in question. Once
again, a dossier of studies elucidating product chemistry, toxicology, and environmental effect is submitted via R4BP3. The assessment must be completed by the
MS CA within 1 year. A further provision for ‘candidates for substitution’ is applied
at this point, the procedure of ‘comparative assessment’ (see Article 28 of the BPR).
In the case of applications for the authorization of products containing active substances that are candidates for substitution, the MS CA must conduct an assessment
to determine “If there is already an authorised product, which is sufficiently effective, presents no other significant economic or practical disadvantages and does not
affect the occurrence of resistance in the target organism, the new product will be
restricted or prohibited.” Once again, these provisions, of course, apply to ARs.
Comparative assessment (European Commission 2016a) is a new and as yet,
untested regulatory procedure, and there is much uncertainty about how it is to be
implemented by the Commission and MSs. It seems to be a global regulatory ‘first’,
wherein a product is considered by regulators to be both effective and safe, and with
a full supporting dossier of regulatory studies obtained by a manufacturer at considerable cost, is denied access to the market because an assessment is made that an
alternative is equally effective and safer. Both of these concepts are notoriously
difficult to quantify with precision, and the provision for comparative assessment
seems ripe for legal challenge.
Application for product authorization in only one EU MS is rare. This is because
it is an important purpose of the BPR is to expedite movement of products throughout the EU and to harmonize the regulation of ARs among MSs, thereby, reducing
costs for manufacturers and users. The procedure of ‘mutual recognition’ is intended
to facilitate this process. In this mechanism, an initial application is made to a single
MS, called the reference Member State (rMS), which conducts an initial assessment
of the submitted product regulatory dossier. When the rMS has granted an authorization, the applicant notifies the CAs of all other MSs (called concerned Member
States, cMS) where authorizations are required. These cMSs must either grant or
deny authorization within 5 months, without the need for any detailed examination
of the product dossier. If one or more cMS is not prepared to issue authorization
under mutual recognition, the dossier is referred for decision to an ECHA coordination group, comprised of representatives of MS CAs, which must reach a decision
within 60 days. If this fails, the final arbiter is the Commission.
In practice, it is rare indeed for any of these required time-scales to be achieved
by the Commission and MS CAs. It is equally rare for a cMS to issue an authorization by mutual recognition without recourse to the original product dossier and
more detailed consideration of the product in question in the context of national
priorities. Therefore, once again, a key purpose of the BPR is not achieved. Indeed,
far from resulting in harmonized product use patterns and product labels across the
EU, the implementation of the BPR seems to have crystalized the different regulatory approaches, and concerns, among the countries involved. No attempt will be
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made here to summarize the status of AR regulation in each EU MS because these
are highly varied and constantly changing, but here are a few examples:
• In some countries, particularly in Germany, Holland, Belgium and Scandinavian
MSs, second-generation anticoagulants cannot be sold to and used by amateurs
(see Chap. 12 for definitions of user groups) – even in the small packs that have
been previously available to them for decades. (A similar restriction has been
recently been imposed on amateur in the US by the US EPA.) In others, particularly in the UK and countries of southern Europe, such products remain available
to amateurs because these MSs consider that effective rodenticides must be
available to the public to protect their health and well-being. Products, pests, and
use patterns are identical, but regulatory approaches of the MS CAs differ completely when weighing the balance between public health and environmental
risk.
• Products containing bromadiolone have been removed from the market in the
Netherlands after the publication of a report that resistance to this active substance occurs in some parts of the country (Meerburg et al. 2014). However, a
survey of anticoagulant resistance among house mice in Germany (Pelz et al.
2012) has found resistance to the first-generation anticoagulants in 24 out of 25
sites examined. In spite of this conclusive evidence of widespread resistance, the
German CA has introduced a regulatory scheme in which only the widely-
resisted FGARs are to be made available to amateurs for mouse control.
• Because of the widespread resistance in UK Norway rats to difenacoum and
bromadiolone (Buckle 2013), the CA (the Health and Safety Executive) has just
removed a 30-year-old ban on the use of resistance-breaking products based on
brodifacoum and flocoumafen outside buildings; thus, permitting them to be
used for the first time for the control of rat infestations. However, the regulatory
authorities of several Nordic countries are now introducing just such a ban on the
use of these products outdoors.
• The most common pattern of use of all ARs in the EU is “in and around buildings,” and there is a sensible definition of this pattern of use provided by the EC
(European Commission 2009), which permits AR application wherever rats
infesting buildings are found to live, both indoors and out. However, this has not
prevented MSs from ignoring this definition and introducing their own. For
example, in Spain, AR application ‘around’ a building is permitted only up to
2 m from the walls of the building. Thus, control action cannot be taken at the
site of infestations and, instead, practitioners are permitted to apply bait only
within 2 m of the facility to which they are trying to prevent rodent ingress.
The European Commission attempted to reassert harmony into this disparity by
employing a group of EU government and academic experts to assess and report on
effective and proportionate risk mitigation measures for ARs (Berny et al. 2014).
However, there is little sign that this initiative has had any effect on the differing
regulatory perspectives of the EU MS CAs to the ARs.
The processes of implementation of the BPR are described in more detail on the
website of ECHA (http://echa.europa.eu/). There is also a particularly useful series
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of web-pages at the website of the UK CA, the Health and Safety Executive (http://
www.hse.gov.uk/biocides/index.htm).

4.3

Consequences of the BPD/BPR and Streamlining

There is little doubt that the implementation of the BPD and BPR has placed a massive strain on the regulatory resources of the European MSs. Staff members of MS
CAs have to take on an additional workload and travel to cover European responsibilities in addition to ongoing national duties. However, an initial lack of resources
within the CAs of many (if not all) EU MSs, only now slowly being remedied, has
resulted in implementation time-tables for the BPD, and latterly the BPR, being set
back on numerous occasions. The time-table for BPR implementation is now running about 10 years behind that originally envisaged.
Two novel procedures have been implemented to streamline the process and to
save the resources of regulators and manufacturers alike. The first is a process called
‘Union Authorisation’ (UA). This is now intended to provide an element of harmonization that has not been delivered by the process of mutual recognition. To achieve
a UA, an applicant must again engage first with an rMS designated by
ECHA. However, the procedure of mutual recognition (i.e., national recognition of
the rMS authorization by other MSs) is replaced by Union-wide authorization
granted by ECHA and the European Commission. The mechanism used by ECHA
for granting UAs is through the BPC and similar to the one applied for active substances (see above). This approach is generally welcomed by manufacturers,
although national CAs are wary of it, as they lose the power to determine what
biocides are used in their territories.
A second attempt at streamlining is provided by the ‘Biocidal Product Family’
(BPF) concept. In this, a manufacturer submits a dossier of information and obtains
an authorization for a ‘frame formulation’. This is a generalized formulation containing a series of specified components, which may itself never be sold. Several, or
indeed many products, can then be put on the market under the initial authorization
as long as data is provided to show any variations from the frame formulation meet
specified narrow guidelines with respect to any differences, and present risks that
are lower than those of the frame formulation itself. Once again, this innovation is
welcomed by manufacturers but it remains to be seen if its implementation by MS
CAs will meet its objectives of reducing regulatory workload and providing
enhanced protection of human health and the environment.
A series of studies of the impacts of these regulatory instruments on the availability of biocidal products and on product innovation has been carried out both by
the Commission and by industry. The most recent, conducted by the International
Association for Soaps, Detergents and Maintenance Products (A.I.S.E.) and the
European Biocidal Products Forum of the Confederation of European Chemical
Manufacturers (Cefic), has shown that a predicted 25% of all existing biocidal products will leave the market in the coming years (AISE/EBPF 2015).
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Although it is impossible to quantify, the effect of these regulations on industry
innovation has been considerable. Budgets that would have been committed to the
development of novel active substances and new biocidal products have instead
been spent to keep existing products on the market (AISE/EBPF 2015). The stated
objectives of the BPD/BPR are laudable, namely the harmonization of biocidal
product authorization across the countries of the EU and, thereby, the enhanced
protection of human health and the environment. However, 17 years after the publication of the BPD, and with vast resources of time and money already expended, it
is can be said, with reasonable confidence, that these objectives are far from being
fully achieved.

4.4

Decision of the ECHA Risk Assessment Committee on ARs

A recent decision made by ECHA’s Risk Assessment Committee (RAC) looks set to
alter radically the regulatory landscape for ARs in the EU. RAC has decided to classify all ARs as “toxic to reproduction” (European Commission 2016b). This decision has been made on the basis that all ARs are analogous to warfarin, a known
teratogen, and in spite the fact that toxicological studies on all other ARs show little
evidence of teratology. Nevertheless, a Specific Concentration Limit (SCL) has
been set at 30 ppm for all AR active substances, and products containing them at
greater concentrations must carry an appropriate label statement. EU regulation prevents any products so labelled from being sold to, and used by, amateurs and, at
first, this was thought to be the main regulatory effect. However, further consideration has found that some professionals may not wish to use these products, and
their customers may not want them deployed on their premises, especially where
there is general public access. It seems likely, therefore, that there will be a shift
from 50 ppm to <30 ppm concentration in many SGAR products, with possible
effects on product efficacy and resistance development. Effective FGAR products
are implausible with active ingredient concentrations <30 ppm, and the place of this
group of substances in the EU rodenticides market seems increasingly tenuous.

4.5

The Plant Protection Products Directive and Regulation

The general statement that rodent depredations of growing crops in the EU are seldom of great financial consequence is undoubtedly true (Buckle and Pelz 2015),
although this is no consolation to those farmers and growers who occasionally do,
indeed, sustain severe damage to their valuable crops and produce. In particular,
damage to grassland and fodder in some parts of eastern France and Switzerland
may be catastrophic during the periodic cyclical fluctuations of some vole species.
Severe damage is also reported in young forestry plantations in the countries of
Fennoscandia and in fruit orchards across continental Europe. There are also

11 An International Perspective on the Regulation of Rodenticides

309

cyclical outbreaks of damage by voles to fruit, cereal and fodder crops across
Europe, from Portugal in the west to the countries of the former Yugoslavia in the
east.
The use of rodenticides for crop protection, however, brings risks in addition to
those presented by rodenticides used as biocides. In particular, when ARs are
applied for the protection of broad-acre, orchard and forestry crops, risks to wildlife
and the wider environment, particularly potential contamination of soil and water,
are of special concern. This is because crop protection application methods do not
confine rodenticides to protected bait stations and rodenticide baits that are not consumed by target rodents cannot easily be retrieved (see Chaps. 2 and 12).
Furthermore, it is axiomatic that populations of a wide range of wildlife species are
likely to be greater in areas of agriculture and horticulture than in urban and sub-
urban environments. Consequently, the suite of regulatory chemistry, toxicology
and environmental studies required to quantify the risks for AR applications for
crop protection is proportionately increased. This additional regulatory burden, as
well as our current knowledge of the risks of the ARs (the subject of this book), has
resulted in fewer applications of rodenticide active substance approvals, and product authorizations, under the PPPD/PPPR. Indeed, among ARs the only active substances approved for use in plant protection in the EU are chlorophacinone,
difenacoum, and bromadiolone. We must presume that it was an active decision by
manufacturers not to pursue crop protection authorizations of the three most potent
ARs, brodifacoum, difethialone, and flocoumafen.
The processes of active substance approval and product authorization for rodenticides through the PPPR are similar to those already described for the BPR and will
not be further discussed. However, the MS CAs that assess crop protection AR uses
are often different to those employed for biocides. For the former, MS departments
and ministries of agriculture usually provide CA representation, whereas for biocides, representatives generally come from ministries of health.

4.6

Possible Effects of ‘Brexit’

At the time of writing, little is known of the precise nature of the cessation of membership of the EU by the UK (‘Brexit’) and how it will be implemented. What follows is, therefore, speculative. However, Brexit seems unlikely to have a profound
effect on the way that ARs are regulated in the UK. Obviously, UK manufacturers
wishing to export rodenticide products into the EU will remain bound by its rules.
Classification, labelling and packaging is overseen the ECHA Risk Assessment
Committee (RAC) and, while no longer bound to do so, the UK Competent Authority
for biocides (HSE) would have to have very firm scientific grounds to deviate significantly from decisions made by that body. In terms of the more practical aspects
of AR use, such as who may use these products and where they may be applied,
there has been such disagreement among EU Member States (see above) that the
principle of harmonization, fundamental to the EU policy of free movement of
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goods, has been partially set aside in the case of products containing the ARs. HSE
is therefore likely to continue its current regulatory policies on the sale and use of
ARs in the UK for the foreseeable future.

5
5.1

Regulation of Anticoagulant Rodenticides in Australia
Rodenticides: Past

The evolution of rodenticide regulation in Australia is not unlike what occurred in
the US since the 1940’s with initial and current legislation enacted to ensure
agricultural-focused uses were effective and safe for consumers. In Australia, all
rodenticides, irrespective of use pattern, are considered agricultural chemicals as
defined in the AgVet Code, which is a schedule to the Agricultural and Veterinary
Chemicals Code Act 1994 (www.comlaw.gov.au/Series/C2004A04723”\t”_blank”).
Pre-1950, rodenticides were non-selective acute poisons like strychnine, arsenic,
phosphorous, and thallium sulphate. After the second-world-war, sodium monofluroacetate, organochlorines, and organophosphates were also approved for agricultural crop protection (Ryan and Jones 1972). From 1970 to 1980, the reactive
emergency-use of acutely toxic chemicals were without exception permitted, coordinated and managed by state government agencies and gradually fewer of these
classes of chemicals were used for the manufacture of poison laced grain until only
strychnine remained. Just as in the US, during the 1980s, progressive restrictions
around pesticide use increased. By 1996, emergency use of strychnine as an in-crop
rodenticide ceased altogether. This coincided with the approval of zinc phosphide as
a rodenticide and a commercially manufactured ready-to-use laced grain product in
1997. Zinc phosphide remains, to this day, the only approved rodenticide active for
in-crop or in-field agricultural applications not requiring bait stations, but it is not
approved for commensal rodent control. Coumatetralyl (SGAR) has limited in-field
uses for sugarcane, macadamias and pineapples, in bait stations.
The availability of ARs for commensal rodent control around homes and other
built environs and infrastructure resulted in this class of rodenticides rapidly overtaking the use of acute poisons on a volume basis. Their original and currently
approved use patterns made them readily accessible to the general public, and over
time this has increased the risk of human exposure and non-target hazards, which
has led to a commensurate increase in federal and state/territory government legislation and regulation aimed at mitigating human exposure risks and to a lesser extent
environmental toxicity risks.
Legislation and regulation controlling the approval and use of pesticides in
Australia was up until 1993 enacted and set by six independent states and two territories. This legislative and regulatory duplication exists because each state was
formed as and remained a partly self-governing British colony up until 1901, after
which they agreed to Federate and become states of a single nation, Australia.
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During federation, Australia’s national constitution and federal government were
adopted, and the power conferred to the Commonwealth federal government did not
extend to the approval of what chemicals could be used, nor how chemicals could
be used in the states and territories.

5.2

Rodenticides: Contemporary Times

Almost 100 years later, Australia’s state and territory governments identified the
need to improve the registration process and labelling of agricultural and veterinary
chemicals with a view to (1) achieving national uniformity in the registration and
approval of chemical supply and use, and (2) establishing a mechanism for systematically reviewing chemicals authorized for sale and use under existing state and
territory-based registration schemes.
As a result, in 1991 the Commonwealth, states and territories agreed to establish
the National Registration Scheme (NRS) for agricultural and veterinary chemicals.
The creation of the NRS was enabled through the Agricultural and Veterinary
Chemicals Act 1988 (www.legislation.gov.au/Details/C2004A03684) and sought to
place under one national umbrella the assessment and registration of all Agvet
chemical products. The NRS was operated by the National Registration Authority
(NRA) created in 1993 under the Agricultural and Veterinary Chemicals
(Administration) Act 1992 (http://www.austlii.edu.au/au/legis/cth/consol_act/
aavca1992511/) as an independent statutory authority. The NRA was responsible
for the implementation of the Agvet Codes that are schedules to the Agricultural and
Veterinary Chemicals Code Act 1994. These detailed the provisions allowing the
NRA to evaluate, approve/register and review active constituents and agricultural
and veterinary chemical products (and their associated labels); to issue permits and
to license the manufacture of veterinary chemical products. It also contains provisions for controls to regulate the supply of chemical products; and provisions ensuring compliance with, and for the enforcement of, the code. Although the national
regulator was and is responsible for chemical and product approvals, their legislative reach extended only to the point of sale of pesticide products. Once rodenticide
products were in the hands of end-users, which depending on scheduling may
require supply via Australian state or territory agency employees, it was the responsibility of the state/territory governments to ensure compliance to the control of use
regulations in each state/territory. This is arguably to the detriment of product effectiveness given the control of use regulations are not consistent between Australian
states and territories, which is a situation mirrored in the US and between EU member states.
The Australian regulatory authority changed its name in 2003 to the Australian
Pesticides and Veterinary Medicines Authority (APVMA). The reasoning for the
name change was two-fold: firstly, it was inconsistent with international nomenclature practised by other international chemical regulators within the Organization for
Economic Cooperation and Development (OECD), which sets the international
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Table 11.3 Scheduling of rodenticide products according to the Standard for the Uniform
Scheduling of Medicines and Poisons (SUSMP) (Gill 2016)
Schedule 5.

Schedule 6.

Schedule 7.

Caution – Substances with a low potential for causing harm, the extent of which
can be reduced through the use of appropriate packaging with simple warnings
and safety directions on the label.
Poison – Substances with a moderate potential for causing harm, the extent of
which can be reduced through the use of distinctive packaging with strong
warnings and safety directions on the label.
Dangerous Poison – Substances with a high potential for causing harm at low
exposure and which require special precautions during manufacture, handling
or use. These poisons should be available only to specialised or authorised
users who have the skills necessary to handle them safely. Special regulations
restricting their availability, possession, storage or use may apply.

standards and benchmarks for chemicals management, and secondly, and somewhat
humorously, a survey in 1998/99 highlighted the acronym was often confused with
the National Rifle Association in the US.
The APVMA was now, like the US EPA, responsible for all agricultural chemical
active ingredient and product approvals, which currently number, 2687 and 8446
respectively. Of the 8446 approved products, 166 are rodenticides (all classes), 135
are SGARs, 13 are FGARs and 18 are others (e.g., zinc phosphide, alphachloralose,
cholecalciferol (Table 11.3) . From the inception of the Australian regulator to the
present day, the approval process for new products or labels standardizes all chemical assessments, labelling and packaging by requiring a consistent package of data
and taking into account proposed product use as stated on the label.
In addition, the application assessment process involves allocating a ‘Schedule’
to a new agricultural chemicals and products based on their overall hazard, taking
into account information about their toxicology, environmental toxicity and proposed use. Scheduling of chemicals and products is the responsibility of the
Australian Committee for Chemicals Scheduling (ACCS) who use the Standard for
the Uniform Scheduling of Medicines and Poisons (SUSMP) (www.legislation.
gov.au/Details/F2016L00849), which takes its legislative imprimatur from the
Therapeutic Goods Act 1989. There are 10 Schedules that are applied to all agricultural and veterinary chemicals and products. Acutely toxic rodenticides (e.g., zinc
phosphide baits and fumigant products) have all been allocated a Schedule 7.
SGARs and FGARs are in the main allocated a Schedule 6, but there are nine products containing either warfarin or coumatetralyl that have been allocated to Schedule
5 (Table 11.4) .
As occurs in the EU and the US, the APVMA has powers under sections 31 to 34
of the Agricultural and Veterinary Chemicals Code Act 1994 to conduct reviews of
registered chemicals. In broad terms, these powers include the authority to reconsider the approvals of active constituents and the registration of products and their
labels, and to require registrants to provide information that may not have been
required for the assessment of original product registrations.
In February 2016, the active constituents: brodifacoum, bromadiolone, difenacoum, difethialone, and flocoumafen were placed on a priority list for reconsideration.
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Table 11.4 Rodenticide
active ingredients and
number of rodenticide
products currently by the
APVMA in Australia

Active constituent
Brodifacoum
Bromadiolone
Coumatetralyl
Difenacoum
Difethialone
Diphacinone
Flocoumafen
Warfarin
Total

SGARa
SGAR
SGAR
SGAR
SGAR
FGARb
SGAR
FGAR

Number of Approved
Products
62
33
6
37
10
1
5
6
160

Second Generation Anticoagulant Rodenticide
First Generation Anticoagulant Rodenticide

a

b

Scoping of the reconsideration is to commence in December 2016, with the reconsideration to commence at a later date taking into account relevant, new scientific
information available since their original approvals with the following facts taken
into account in the prioritization decision:
• These chemicals persist in organs of poisoned rodents and present a risk to non-
target animals that feed on poisoned animals or carcasses.
• Use of products in domestic premises, animal production facilities and food production facilities is currently allowed. This presents potential risks to humans,
pets and wildlife through accidental poisoning. Around 1400 human exposure
incidents to rodent baits are reported to Poisons Information Centres annually.
• Products are not intended for use in crops or the field, though some labels make
it difficult to discern this.
• Use of liquid formulations are a concern because they are not designed for use in
bait stations.
Fortunately, the registration reconsideration process does take into account the
downside risks and in this case the APVMA has pragmatically identified that removing SGARs carries with it the risk that less effective anticoagulants will be the only
option for controlling rodents in commensal situations. The registration reconsideration process that began in February 2016 for these SGARs is not yet complete,
so the implications for SGAR regulation in Australia remains to be seen.

6

Conclusion

Rodents inflict damage to growing crops, grasslands, orchards, and fodder (Buckle
and Pelz 2015); foodstuffs by direct consumption and contamination during storage, production, transport and sale; physical damage to property, installations and
belongings; and perhaps of greatest importance, the transmission of diseases to
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humans and domesticated animals (see Chap. 1). Rodenticides, by design, are
lethally toxic, and in most situations this toxicity pathway is not unique to rodents.
Consequently, their use presents a risk to humans and the environment and measures must be taken to lessen the potential risk. Traditionally, and perhaps as it
should be, that responsibility falls to government entities. Government officials, in
turn, use the most basic available tool to them: enacting regulations and implementation procedures. Like most product-driven markets, regulations typically impose
manufacturing and labeling standards on manufacturers, but regulations and risk
mitigation measures are also aimed at the end-user of the products. Ultimately,
proper use, stewardship, and training on the safe use of pesticide products are the
responsibility of the end-user.
This chapter has presented four examples on the development of pesticide regulation in international markets. In each example, the country or collection of countries (EU) followed their own unique path toward current regulatory paradigms, but
ended at essentially the same point, a focus on product performance, and safety to
humans and the environment. In all four regulatory environments, AR use is still
allowed, but they are under increasing scrutiny as a result of growing public concern
and regulatory response to that concern, some of which is justified. However, the
conclusions international regulators are making on the risk and benefits of continued product use and the disparate policies they are adopting, have created an international regulatory environment that is difficult and costly for product manufactures
to navigate. Harmonization of world pesticide regulation standards would serve to
rectify this disparity, but agreement may be extremely difficult, as is being witnessed by the EU harmonization effort.
As was observed in the case of strychnine in the US, the disappearance of products did not occur overnight as a result of a sweeping legislative actions. It took
40 years of study, growing public concern, an executive-level ban on the product, a
series of judicial reviews, and the US EPA’s unwillingness to challenge judicial
decisions, to arrive to the situation today where strychnine is a minor player in the
rodenticide market. It is the opinion of the authors that ARs, especially SGARs, are
experiencing similar regulatory paths. Restrictions on AR use throughout the world
are not being driven by high level congressional, parliamentary actions, or executive
level actions, but are succumbing to the effects of regulatory implementation and
associated risk mitigation measures enacted by well-intentioned regulators.
In many cases, risk mitigation measures are justified for continued use ARs (see
Chap. 12). As pointed out in other chapters of this book, there is a significant body
of evidence that many wildlife taxa are exposed to ARs, in particular SGARs, almost
wherever they are used. Certainly, there is also evidence that some wildlife have
been killed by ARs. That knowledge alone might be justification enough to severely
restrict their use or even ban them. However, no significant advances in rodenticide
chemistry have been made since the introduction of SGARs and cholecalcifereol
more than 30 years ago. The risks and benefits of the old chemistries we rely on are
becoming better understood and it goes without saying that all products come with
their own unique set of issues. Forcing a shift from ARs to other chemistries is simply substituting one set of risks for another.
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As is usually the case, more information is needed properly to evaluate the risks
and benefits of continued AR use. Early research focused heavily on acute effects of
exposure to rodenticide baits and residues in tissues of poisoned animals. Recent
research trends are focused on sub-lethal exposure scenarios and the impact of low-
level, potentially non-lethal levels of residues in the tissues of exposed animals (see
Chap. 3). This is an area that deserves a more in depth understanding. However, it
should also be balanced with an equal understanding of what sub-lethal exposure
actually means in relation to the health of individual animals and their possible
impact on the ability of species to maintain viable populations. The same can be
said for understanding the risks of other exposure scenarios such as repeat exposures and exposure to multiple ARs either concurrently or over time.
A systematic study is warranted of pesticide regulations and the associated success or failure rate of those regulations on meeting their intended objectives. As
pointed out above, changes in product availability provides the opportunity to
observe the direct impact of regulations. This measure alone is not adequate if one
tries to draw conclusions on the real impact on protection of human or environmental protection. For example, as the use of one product decreases and the use of
another increases, questions arise around what new risks have been realized or benefits have been given up. In reality, funding for this type of research is extremely
limited. Government regulators are typically inadequately funded and there is little
incentive for industry to conduct this research. It is essential however, that regulators take informed and balanced positions, and do not act precipitately, in the
absence of concrete information. Application of unreasonable risk mitigation could
result in the loss of valuable products, potentially resulting in unacceptable levels of
loss to food supplies and increased risk of negative impacts to human health and
safety.
It is apparent that the number of years AR products will be available for operational rodent management is limited. Such is the life of any pesticide product.
Whether it is a growing understanding of a product’s unanticipated consequences,
target pests developing resistance to chemistries, growing public concern, or over-
regulation, a pesticide product’s days are numbered beginning the day it is first
registered. In the case of rodenticides, you only need to look at strychnine, red
squill, and arsenic-based products to observe the life of a pesticide. In many
instances, this obsolescence is warranted. As presented above, the perception of the
risk and benefit of SGARs varies among governments. The availability of SGARs is
likely shorter in the US than other countries. What will be the next in line in the
evolution of rodenticides? Perhaps it will be simple reformulation of existing active
ingredients. Will that meet future rodenticide needs into the twenty second century?
The future more than likely lies in the development of new active ingredients, biological agents and novel technologies that have a higher degree of target species
specificity. However, the costs necessary to bring a new active ingredient to market
are extremely high and the time-frames very long. Risk of failure, low market
potential and short product life, only lessens the desire or ability of a private manufacture to invest in such an endeavor.
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One thing is certain, the quest for new rodent management techniques, including
rodenticides, will be never-ending. Adequate scientific understanding of the risks
and benefits accompanying new technologies will lag behind product development
and as a result, regulations will be reactionary as regulators address the impacts of
new technologies. Perhaps, as is currently being attempted in the EU, governments
will work out harmonized international regulatory standards and systems, thereby
reducing the costs and time required to bring new safer, more effective technologies
to market.
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